ライフサイエンスコーパス: sphingomyelinase

1 ngomyelin (acid sphingomyelinase and neutral sphingomyelinase).

2 by interfering with membrane-associated acid sphingomyelinase).

3 ion of cholesterol and inhibition of neutral sphingomyelinase.

4 regulated by lipids such as cholesterol and sphingomyelinase.

5 lls were treated with exogenous ceramide and sphingomyelinase.

6 mide, and manumycin, an inhibitor of neutral sphingomyelinase.

7 tment of cells with 25-hydroxycholesterol or sphingomyelinase.

8 locked by pharmacological inhibition of acid sphingomyelinase.

9 h is prevented by genetic deficiency of acid sphingomyelinase.

10 ation of voltage-gated K+ (Kv) channels by a sphingomyelinase.

11 matrix degradation mediated by IL-1, TNF, or sphingomyelinase.

12 gers the activation of acid, but not neutral sphingomyelinase.

13 icrotiter assay was developed using purified sphingomyelinase.

14 phatidylcholine-specific phospholipase C and sphingomyelinase.

15 ced or restored by extracellular exposure to sphingomyelinase.

16 with an on-tissue digestion by ceramidase or sphingomyelinase.

17 mmatory signaling in HRECs by downregulating sphingomyelinases.

18 The level of SM is tightly regulated by sphingomyelinases.

19 s via agonist-induced activation of cellular sphingomyelinases.

20 f labeled LDL (0.5 mg/mL of total lipids) to sphingomyelinase (0.0-0.2 unit/mL) led to modest particl

21 r, by the silencing or inhibition of neutral sphingomyelinase 2 (nSMase-2) using shRNAi, scyphostatin

22 Recently, we reported that neutral sphingomyelinase 2 (nSMase2) functions as a bona fide ne

23 Neutral sphingomyelinase 2 (nSMase2) is one of the key enzymes r

24 We previously presented that the neutral sphingomyelinase 2 (nSMase2) is the only SMase activated

25 Neutral sphingomyelinase 2 (nSMase2), encoded by the Smpd3 gene,

26 bserved in astrocytes with deficient neutral sphingomyelinase 2 (nSMase2), indicating that ceramide g

27 3 gene coding for the active site of neutral sphingomyelinase 2 (NSMase2), secreted increased amounts

28 Neutral sphingomyelinase 2 (nSMase2, product of the SMPD3 gene)

29 nduces ceramide accumulation through neutral sphingomyelinase 2 and that ceramides shift the Bcl-x 5'

30 x 5'SS selection in INS-1 cells, and neutral sphingomyelinase 2 inactivation only partially prevented

31 s by inhibiting ceramide synthase or neutral sphingomyelinase 2 leads to translocation of membrane-bo

32 lated protein 2, Janus kinase 3, and neutral sphingomyelinase 2 proteins localized to breast tumor en

33 PP2A activation by IL-1beta involved neutral sphingomyelinase-2 (NSMase-2) and an accumulation of cer

34 ion of the plasma membrane localized neutral sphingomyelinase-2 (NSMase-2).

35 locked by inhibition or silencing of neutral sphingomyelinase-2 (nSMase2).

36 ral exosome secretion due to lack of neutral sphingomyelinase-2 function, that ceramide-enriched exos

37 cation of a sphingomyelin hydrolase (neutral sphingomyelinase-2) to the plasma membrane.

38 tisense knockdown of N-SMase, but not acidic sphingomyelinase (A-SMase), suggests that soluble produc

39 tabolism, including a fatty acid elongase, a sphingomyelinase, a phosphate acyltransferase, and a pat

40 Sphingomyelin breakdown as a result of sphingomyelinase activation after ligation of a variety

41 ly, bilirubin triggered rapid Ca(2+) influx, sphingomyelinase activation, formation of ceramide, and

42 Factor associated with neutral sphingomyelinase activity (FAN) is an adaptor protein th

43 Ablation of sphingomyelinase activity also interfered with the abili

44 through the regulation of pH-dependent acid-sphingomyelinase activity and of RhoA-dependent transpor

45 (5) integrin, leading to suppression of acid sphingomyelinase activity and preventing ceramide-mediat

46 rophil-mediated lung injury through both its sphingomyelinase activity and syndecan-1.

47 's hemolytic activity is consistent with its sphingomyelinase activity and the observation that Rv088

48 that the Mtb protein Rv0888 possesses potent sphingomyelinase activity cleaving sphingomyelin, a majo

49 However, mutant beta-toxin mice deficient in sphingomyelinase activity failed to trigger features of

50 Acid sphingomyelinase activity in pRBCs was associated with t

51 Acid sphingomyelinase activity in pRBCs was associated with t

52 hemolysis and lymphotoxicity, are due to the sphingomyelinase activity of the enzyme.

53 We mimicked the effect of sphingomyelinase activity on lipid mixtures of palmitoyl

54 These studies provide evidence that acid sphingomyelinase activity plays an essential role in the

55 s favor an indirect mechanism involving acid sphingomyelinase activity rather than a direct interacti

56 However, increased neutral sphingomyelinase activity was observed in hepatocytes fr

57 s as biofilm ligase activity, independent of sphingomyelinase activity) producing an insoluble nucleo

58 t of pRBCs with amitriptyline inhibited acid sphingomyelinase activity, ceramide accumulation, and mi

59 t of pRBCs with amitriptyline inhibited acid sphingomyelinase activity, ceramide accumulation, and mi

60 ur group demonstrated that secretion of acid sphingomyelinase acts upstream of ERM dephosphorylation,

61 catalyzed by the intestinal enzyme alkaline sphingomyelinase (alk-SMase, NPP7, ENPP7).

62 otecting cells by mediating the secretion of sphingomyelinase, an enzyme that reduces the number of a

63 e, we demonstrate that beta toxin, a neutral sphingomyelinase and a virulence factor of S. aureus, fo

64 rticles might stimulate the activity of acid sphingomyelinase and activate the apoptotic machinery.

65 eep red blood cells by Staphylococcus aureus sphingomyelinase and CAMP factor (cohemolysin), a secret

66 s that was dependent on expression of acidic sphingomyelinase and CD95.

67 ide was primarily due to the actions of acid sphingomyelinase and ceramide synthase LASS 5, demonstra

68 ihydroceramides along with elevation of acid sphingomyelinase and CerS5 activities.

69 ins of S. aureus, induces activation of acid sphingomyelinase and concomitant release of ceramide in

70 however, combined inhibition of both acidic sphingomyelinase and de novo ceramide generation was req

71 nd via the hydrolysis of sphingomyelin (acid sphingomyelinase and neutral sphingomyelinase).

72 Lipid-modifying enzymes including sphingomyelinase and phosphoinositide kinases regulate t

73 amide was inhibited by D609, an inhibitor of sphingomyelinase and SM synthase.

74 In this study, the requirement for acid sphingomyelinase and sphingomyelin metabolites in the TN

75 2 (nSMase2) functions as a bona fide neutral sphingomyelinase and that overexpression of nSMase2 in M

76 Abeta1-42 peptides induced the activation of sphingomyelinases and the production of ceramide in neur

77 , lipid/raft perturbations (cyclodextrin and sphingomyelinase), and bleb formation.

78 Arachidonic acid activates the acid sphingomyelinase, and inhibition of acid sphingomyelinas

79 ncrease in serine palmitoyltransferase, acid sphingomyelinase, and neutral sphingomyelinase mRNA, pro

80 red exocytosis of lysosomes, release of acid sphingomyelinase, and rapid lesion removal by caveolar e

81 ention such as lipoprotein lipase, secretory sphingomyelinase, and secretory phospholipase A2.

82 mily A, member 12), glucocerebrosidase, acid sphingomyelinase, and transglutaminase 1.

83 inds 125I-PFO* only after SM is destroyed by sphingomyelinase; and (3) a residual pool that does not

84 yeast two-hybrid screen and identified acid sphingomyelinase as a novel intracellular signaling path

85 ism mediated by activation of secretory acid sphingomyelinase, as suggested by experiments with neutr

86 th CD161, and this association augments acid sphingomyelinase (ASM) activity upon stimulation of CD4(

87 disease (NPD) is caused by the loss of acid sphingomyelinase (ASM) activity, which results in widesp

88 rage disorder caused by a deficiency in acid sphingomyelinase (ASM) activity.

89 embranes and subsequent inactivation of acid sphingomyelinase (ASM) and thus work as functional ASM i

90 We have identified acid sphingomyelinase (ASM) as an important player in the ear

91 r a targeted deletion (knockout) of the acid sphingomyelinase (ASM) gene (called ASMKO mice), a faith

92 Acid sphingomyelinase (ASM) hydrolyzes sphingomyelin to ceram

93 In mammals, acid sphingomyelinase (ASM) is an enzyme that hydrolyzes sphi

94 Acid sphingomyelinase (ASM) is an important early responder i

95 We show that acid sphingomyelinase (ASM) is increased in fibroblasts, brai

96 key enzyme in sphingolipid metabolism, acid sphingomyelinase (ASM) is involved in the regulation of

97 tudy, we show that the lysosomal enzyme acid sphingomyelinase (ASM) is released extracellularly when

98 The lipid hydrolase enzyme acid sphingomyelinase (ASM) is required for the conversion of

99 Acid sphingomyelinase (ASM) is the lipid hydrolase that is de

100 se is caused by a genetic deficiency in acid sphingomyelinase (ASM) leading to the intracellular accu

101 Acid sphingomyelinase (ASM) mediates the formation of membran

102 Here we show that inhibition of acid sphingomyelinase (ASM) mislocalizes both the K-Ras isofo

103 Acid sphingomyelinase (ASM) released from lysosomes induces e

104 nt exocytosis of lysosomes, delivery of acid sphingomyelinase (ASM) to the outer leaflet of the plasm

105 tudy was performed to determine whether acid sphingomyelinase (Asm), a ceramide-producing enzyme, is

106 In particular, acid sphingomyelinase (ASM), a critical enzyme in the product

107 s been previously shown to activate the acid sphingomyelinase (Asm)/ceramide system.

108 Acid sphingomyelinase (ASM; E.C. 3.1.4.12) is best known for

109 /or a critical enzyme of TNF signaling, acid sphingomyelinase (ASMase(-/-)).

110 g pathways, the molecular mechanisms of acid sphingomyelinase (ASMase) activation remain poorly under

111 Acid sphingomyelinase (ASMase) and neutral sphingomyelinase (

112 ortilin is critical for the delivery of acid sphingomyelinase (ASMase) and required for efficient pha

113 of C(16)-ceramide due to activation of acid sphingomyelinase (ASMase) and sphingomyelin hydrolysis.

114 cocerebrosidase (beta-GlcCer'ase) and acidic sphingomyelinase (aSMase) catalytic activity and enzyme

115 Acid sphingomyelinase (aSMase) catalyzes the hydrolysis of sp

116 l and bis(monoacylglycero)phosphate, an acid sphingomyelinase (ASMase) cofactor, within the RPE.

117 Acid sphingomyelinase (ASMase) converts the lipid sphingomyel

118 Pharmacological inhibition of acid sphingomyelinase (aSMase) decreased anti-DENV NS1 Ab-med

119 required the ceramide-synthesis enzyme acid sphingomyelinase (aSMase) for their release, an enzyme w

120 The acid sphingomyelinase (aSMase) gene gives rise to two distinc

121 Acid sphingomyelinase (aSMase) generates the bioactive lipid

122 Acid sphingomyelinase (ASMase) has been proposed to mediate l

123 The putative acid sphingomyelinase (ASMase) inhibitor imipramine inhibited

124 Translocation of the secretory form of acid sphingomyelinase (ASMase) into microscopic rafts generat

125 ave focused on stress mediators such as acid sphingomyelinase (ASMase) or protein kinase Cdelta (PKCd

126 A defect in acid sphingomyelinase (ASMase) results in SM storage and subs

127 l storage disease caused by the loss of acid sphingomyelinase (ASMase) that features neurodegeneratio

128 An overactivation of sphingomyelinase (ASMase) was noted in the treated cells

129 Acid sphingomyelinase (ASMase)(-/-) mice exhibit LC accumulat

130 ine, a frequently employed inhibitor of acid sphingomyelinase (ASMase), blocked PGE(2) production.

131 sipramine and imipramine, inhibitors of acid sphingomyelinase (ASMase), suppressed RGDfV-induced cera

132 Because cisplatin activates acid sphingomyelinase (ASMase), we investigate here the role

133 vani promastigotes induce activation of acid sphingomyelinase (ASMase), which catalyzes the formation

134 these defense mechanisms by activating acid sphingomyelinase (ASMase), which increases tubulin acety

135 6 melanomas grow 2- to 4-fold faster in acid sphingomyelinase (asmase)-deficient mice than in asmase(

136 tor superfamily receptors might involve acid sphingomyelinase (ASMase)-mediated ceramide generation,

137 he well characterized lysosomal enzyme, acid sphingomyelinase (ASMase).

138 ion (neutral sphingomyelinase [NSMase], acid sphingomyelinase [ASMase], and serine-palmitoyl-transfer

139 ASMase and NSMase activity was determined by sphingomyelinase assay in primary cultures of HRECs.

140 ASM activity was determined using Amplex Red sphingomyelinase assay.

141 ic lipids, we employed recombinant bacterial sphingomyelinase (bSMase) as a direct probe of SM metabo

142 Treatment of cells with Bacillus cereus sphingomyelinase (bSMase) increases the overall ceramide

143 pended on Ca(2+) and the activity of neutral sphingomyelinase but not clathrin-coated pit maturation.

144 provide evidence that SMPDL3A is not an acid sphingomyelinase but unexpectedly is active against nucl

145 kle cell disease enhance the activation acid sphingomyelinase by 13%, resulting in increased producti

146 Activation of acid sphingomyelinase by alpha-toxin is mediated via ADAM10.

147 Inhibition of acid sphingomyelinase by NB-19 before addition of POVPC compl

148 lavoprotein (6.m00467), lysozyme (6.m00454), sphingomyelinase C (29.m00231), and a hypothetical prote

149 Sphingomyelinase C (SMase) inhibits CFTR chloride channe

150 depletion of sphingomyelin by inhibitors or sphingomyelinase caused plasma membrane remodeling, lead

151 The addition of sphingomyelinase, ceramide, or a proteasome inhibitor al

152 fferent terminals is mediated by the neutral sphingomyelinase/ceramide signaling pathway.

153 icate a novel and important role of the acid sphingomyelinase/ceramide system for the endothelial res

154 he phosphatidylinositol 3-kinase and neutral sphingomyelinase chemical inhibitors, Ly294002 and GW486

155 ing to the presence of a venom enzyme called sphingomyelinase D (SMaseD).

156 myelin depletion, as shown using recombinant sphingomyelinase D.

157 abbits injected with purified or recombinant sphingomyelinase D2, Paixao-Cavalcante et al. propose in

158 Ceramide depletion, by myriocin or neutral sphingomyelinase deficiency (fro/fro mouse), led to GSK3

159 delivery of a model therapeutic cargo (acid sphingomyelinase, deficient in Niemann-Pick disease A-B)

160 zing ceramide antibody in mice and with acid sphingomyelinase-deficient fibroblasts.

161 in contrast to asm(+/+)/ldlr(-/-), the acid sphingomyelinase-deficient littermates did not display h

162 acid sphingomyelinase, or obtained from acid sphingomyelinase-deficient mice, and lung inflammation w

163 acid sphingomyelinase, or obtained from acid sphingomyelinase-deficient mice, and lung inflammation w

164 RBCs treated with amitriptyline or from acid sphingomyelinase-deficient mice.

165 RBCs treated with amitriptyline or from acid sphingomyelinase-deficient mice.

166 To test this association in vivo, acid sphingomyelinase deletion (asm(-/-)) was transferred to

167 vo characterization of the T. brucei neutral sphingomyelinase demonstrates that it is directly involv

168 hrough a caspase-mediated process), the acid sphingomyelinase-dependent generation of ceramide, and p

169 ne protein with a surface-exposed C-terminal sphingomyelinase domain and a putative N-terminal channe

170 beta-toxin is a sphingomyelinase encoded for by virtually all S. aureus

171 We also show that acid sphingomyelinase enhances RBC-derived microparticle (MP)

172 Finally, we determined that sphingomyelinase enzymatic activity directly prevents al

173 bination with novel on-tissue ceramidase and sphingomyelinase enzyme digestions makes it now possible

174 alpha-Toxin heptamer formation and acid sphingomyelinase expression were determined by means of

175 donic acid and sequential activation of acid sphingomyelinase for the generation of ceramide within t

176 Substantial homologies to sphingomyelinases from other leptospiras and other bacte

177 due to overexpression of the endogenous acid sphingomyelinase gene.

178 vage pathway of ceramide formation, and acid sphingomyelinase has been implicated, in part, in provid

179 d-type strain reveal that activation of acid sphingomyelinase in endothelial cells requires alpha-tox

180 s study underlines the importance of neutral sphingomyelinase in fibrillar Abeta peptide-induced apop

181 onic acid and highlight the role of the acid sphingomyelinase in microparticle-induced apoptosis of e

182 imed to identify the role of the enzyme acid sphingomyelinase in the aging of stored units of packed

183 imed to identify the role of the enzyme acid sphingomyelinase in the aging of stored units of packed

184 d activity level in HRECs, and inhibition of sphingomyelinases in endothelial cells prevents cytokine

185 e examined the role of beta-toxin, a neutral sphingomyelinase, in S. aureus-induced lung injury.

186 n D-inhibiting drug alisporivir and the acid sphingomyelinase-inactivating drug, desipramine, synergi

187 direct connection to the previously observed sphingomyelinase-induced displacement of cholesterol fro

188 Neutral sphingomyelinase inhibition caused accumulation of miR-1

189 Acid sphingomyelinase inhibition in stored pRBCs offers a nov

190 Acid sphingomyelinase inhibition in stored pRBCs offers a nov

191 h T cell activation; this was abolished upon sphingomyelinase inhibition.

192 Finally, the acidic sphingomyelinase inhibitor desipramine attenuated HDACI/

193 carbocyclic core of the naturally occurring sphingomyelinase inhibitor scyphostatin, from the readil

194 n export via exosomes, which is blocked by a sphingomyelinase inhibitor, GW4869.

195 ery disease incubated with GW4869, a neutral sphingomyelinase inhibitor, whereas polyethylene glycol-

196 Exosome biogenesis/release was blocked using sphingomyelinase inhibitor.

197 by phosphatidylinositol 3-kinase and neutral sphingomyelinase inhibitors.

198 ein with CD4 and coreceptor, we propose that sphingomyelinase inhibits HIV infection by inducing CD4

199 ly, we reported that treatment of cells with sphingomyelinase inhibits human immunodeficiency virus t

200 rm of the parasite indicate that the neutral sphingomyelinase is essential for growth and survival, t

201 Activation of acid sphingomyelinase is linked to degradation of tight junct

202 Acid sphingomyelinase knockout mice are a model of the inheri

203 ives rise to two distinct enzymes, lysosomal sphingomyelinase (L-SMase) and secretory sphingomyelinas

204 ives rise to two distinct enzymes, lysosomal sphingomyelinase (L-SMase) and secretory sphingomyelinas

205 enzymes, beta-glucocerebrosidase and acidic sphingomyelinase, leading to accelerated maturation of S

206 ly secrete a physiologic level of apoE) with sphingomyelinase led to a reduction of apoE secretion by

207 The combination of cholesterol esterase and sphingomyelinase led to a significant alleviation of ene

208 ucing BRB permeability in part by modulating sphingomyelinase levels.

209 The enzyme acid sphingomyelinase-like phosphodiesterase 3B (SMPDL3B) was

210 Sphingomyelinase-like phosphodiesterase 3b mediates radi

211 ave characterized a gene (lk75.3) encoding a sphingomyelinase-like preprotein of 648 amino acids with

212 of neutral (NSMase) but not acidic (ASMase) sphingomyelinase markedly inhibited gp120-mediated apopt

213 he data also suggest that inhibition of acid sphingomyelinase may provide a novel treatment option to

214 eability transition pore formation, and acid sphingomyelinase-mediated ceramide production.

215 beta cytotoxicity; and addition of bacterial sphingomyelinase (mimicking cellular nSMase activity) in

216 Acid (ASMase) and neutral (NSMase) sphingomyelinase mRNA levels and activity were measured

217 nsferase, acid sphingomyelinase, and neutral sphingomyelinase mRNA, providing a mechanistic link for

218 t study underlines the importance of neutral sphingomyelinase (N-SMase) in mediating the damaging eff

219 astroglia induced the activation of neutral sphingomyelinase (N-SMase), production of ceramide, and

220 The neutral sphingomyelinases (N-SMases) are considered major candid

221 Neutral sphingomyelinases (N-SMases) are major candidates for st

222 Neutral sphingomyelinases (N-SMases) are major candidates for st

223 These pathways include sphingomyelinase-, nitric oxide (NO)-, and phospholipase

224 Alkaline sphingomyelinase (NPP7) is an ecto-enzyme expressed in i

225 (mSREBP-1), phosphorylated Akt, and neutral sphingomyelinase (NSMase) are higher, relative abundance

226 Acid sphingomyelinase (ASMase) and neutral sphingomyelinase (NSMase) are key regulatory enzymes of

227 Inhibition of neutral sphingomyelinase (nSMase) blocked HPV, whereas exogenous

228 Neutral sphingomyelinase (NSMase) has been proposed to mediate i

229 ) machinery, although an alternative neutral sphingomyelinase (nSMase) pathway has been suggested to

230 In addition, Abeta activated neutral sphingomyelinase (nSMase), but not acidic sphingomyelina

231 t both message and protein levels of neutral sphingomyelinase (NSMase), which hydrolyzes sphingomyeli

232 mes involved in ceramide generation (neutral sphingomyelinase [NSMase], acid sphingomyelinase [ASMase

233 The neutral sphingomyelinases (nSMases) are considered major candida

234 Hence, we propose to name Rv0888 as SpmT (sphingomyelinase of Mycobacterium tuberculosis).

235 This structure is similar to that of the sphingomyelinases of Listeria ivanovii and Bacillus cere

236 vo exposure to hyperosmotic shock, bacterial sphingomyelinase or C6 ceramide.

237 Inhibition of acidic sphingomyelinase or de novo ceramide generation blocked

238 Release of endogenous ceramides via sphingomyelinase or exogenous ceramide treatments dose-d

239 Down-regulation of either acid sphingomyelinase or LASS 5-attenuated ceramide accumulat

240 ramide to the bath, by addition of bacterial sphingomyelinase, or by hypertonic stress, S358 is rapid

241 mitriptyline, a functional inhibitor of acid sphingomyelinase, or obtained from acid sphingomyelinase

242 mitriptyline, a functional inhibitor of acid sphingomyelinase, or obtained from acid sphingomyelinase

243 s of endogenous ceramide production, neutral sphingomyelinase, or tumor necrosis factor-alpha also in

244 e release using GW4869 to target the neutral sphingomyelinase pathway induced a decrease in intercell

245 The sphingomyelinase pathway rather than ceramide de novo sy

246 exogenously added S1P did not stimulate the sphingomyelinase pathway; however, added [(3)H]S1P was h

247 Acid sphingomyelinase plays important roles in ceramide homeo

248 dogenous ceramide by the action of bacterial sphingomyelinase prevented PMA-induced translocation of

249 cid sphingomyelinase, and inhibition of acid sphingomyelinase prevents microparticle-induced apoptosi

250 gp120 induced the activation of sphingomyelinases (primarily the neutral one) and the pr

251 However, addition of sphingomyelinase produced significant particle aggregati

252 ereas the addition of exogenous ceramides or sphingomyelinase reduces the differences.

253 eriments with hepatocytes revealed that acid sphingomyelinase regulates the partitioning of the major

254 d genetic blockade of cyclophilin D and acid sphingomyelinase renders the high TNF state hyperresista

255 The sphingomyelinases represent the catabolic pathway for N-

256 the yeast homologue of the mammalian neutral sphingomyelinase, resulted in an increased sensitivity t

257 al sphingomyelinase (nSMase), but not acidic sphingomyelinase, resulting in increased ceramide genera

258 nd the enzymatic breakdown of sphingomyelin (sphingomyelinase), results in significant changes in the

259 mal sphingomyelinase (L-SMase) and secretory sphingomyelinase (S-SMase) via alternative trafficking o

260 mal sphingomyelinase (L-SMase) and secretory sphingomyelinase (S-SMase), via differential trafficking

261 Beta toxin is a neutral sphingomyelinase secreted by certain strains of Staphylo

262 Sphingomyelinases secreted by pathogenic bacteria play i

263 c events including cytokine release and acid sphingomyelinase secretion.

264 fter incubation with cholesterol oxidase and sphingomyelinase show that these two enzymes disrupt the

265 ed membrane bending energy elicits a neutral sphingomyelinase (SMase) activity in human erythrocytes.

266 It secretes sphingomyelinase (SMase) C that can suppress CFTR activi

267 Sphingomyelinase (SMase) catalyzes the degradation of sp

268 ngomyelin to ceramide by exogenous bacterial sphingomyelinase (SMase) protected against the endocytos

269 articular chondrocytes were stimulated with sphingomyelinase (SMase) to increase levels of endogenou

270 hemical changes that decrease levels of acid sphingomyelinase (SMase), an enzyme that cleaves sphingo

271 mide (4-HPR, fenretinide), by treatment with sphingomyelinase (Smase), or by exogenous addition of lo

272 SMs) are plasma membrane lipids that undergo sphingomyelinase (SMase)-mediated hydrolysis in the lyso

273 * unless the sphingomyelin is destroyed with sphingomyelinase (SMase).

274 Here, we report that sphingomyelinases (SMase) from human respiratory pathoge

275 ived from the hydrolysis of sphingomyelin by sphingomyelinases (SMases) and implicated in diverse cel

276 Sphingomyelinases (SMases) hydrolyze membrane sphingomye

277 Levels of SM are regulated by sphingomyelinases (SMases).

278 Neutral sphingomyelinase SMPD3 (nSMase2), a sphingomyelin phosph

279 and 97.7% amino acid identity with putative sphingomyelinases Sph2 and Sph1 (N terminus) from L. int

280 Notably, extracellular addition of sphingomyelinase stimulates host cell endocytosis, enhan

281 stic effect between cholesterol esterase and sphingomyelinase, suggesting that mere aggregation of LD

282 itor, SR33557, but not inhibitors of neutral sphingomyelinase, suppressed RGDfV-induced apoptosis, su

283 Biochemical purification of neutral sphingomyelinases that correlated with MOMP sensitizatio

284 iae member of the extended family of neutral sphingomyelinases that regulates the generation of bioac

285 DNase I folding superfamily; in addition to sphingomyelinases, the proteins most structurally relate

286 gents or by the addition of recombinant acid sphingomyelinase to the culture media, and the corrected

287 Furthermore, sphingomyelinase treatment did not affect the membrane d

288 e decrease in CD4 lateral mobility following sphingomyelinase treatment in terms of clustering of CD4

289 ation of fusion intermediates indicated that sphingomyelinase treatment inhibited HIV at a step in th

290 Notably, sphingomyelinase treatment of cells did not influence gp

291 At low cholesterol concentrations, after sphingomyelinase treatment, the diffusion coefficients a

292 diffusion of CD4 decreased 4-fold following sphingomyelinase treatment, while the effective diffusio

293 pool that does not bind 125I-PFO* even after sphingomyelinase treatment.

294 Exogenous C(6)-ceramide and sphingomyelinase treatments mimicked the influence of do

295 Wounding or exposure to sphingomyelinase triggered endocytosis and intracellular

296 neutral (N-SMase), but not acidic (A-SMase), sphingomyelinase was involved in Abeta1-42-mediated neur

297 phospholipases, aspartyl proteases, and acid sphingomyelinases) was found in the M. globosa genome.

298 vasoconstriction and responses to exogenous sphingomyelinase were increased, whereas the responses t

299 We show that CCN1 activates neutral sphingomyelinase, which functions as a key source of CCN

300 Consistently, inhibition of acid sphingomyelinase with imipramine disrupts ACEC formation